AzTrials
AzTrials

CIPN - Chemotherapy-Induced Peripheral NeuropathyProprioCIPNNCT07367711

The Influence of Chemotherapy on Position Sense

An observational study of CIPN - Chemotherapy-Induced Peripheral Neuropathy and Chemotherapy-Induced Peripheral Neuropathy, run by KU Leuven at 1 site in Belgium.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most prevalent side-effects of chemotherapy, causing sensory and motor symptoms in patients. CIPN development is especially prevalent in chemotherapy treatment involving platinum- and taxane-based agents. Read more about this study

Who is it for?
Ages 18 to 75 yearsHealthy volunteers can take part
What is being tested?
Questionnaire - Edinburgh Handedness Assessment, Questionnaire - QuickDash and Questionnaire - EORTC QLQ-CIPN20
How many people
145 participants
Where
1 siteBelgium
Study dates
Feb 2026to Nov 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Adult individuals diagnosed with breast cancer or healthy controls. One patient group having undergone only breast cancer surgery. Second patient group having undergone both breast cancer surgery and chemotherapy with taxane or platinum-based chemotherapeutic agents. A third group of sex and age-matched healthy controls. Patients will be recruited in cooperation with the department of the Multidisciplinary Breast centre of the University Hospital of Leuven.

Who may be able to join

  • General (applies to all participants):
  • At least 18 years of age at the time of signing the informed consent form
  • Voluntary written informed consent of the participant has been obtained prior to any screening procedures
  • Breast cancer surgery-only patient group:
  • The patient is an adult oncological person between 18 and 75 years old who has been treated for cancer
  • The participant has undergone breast cancer surgery but has not received any radiotherapy or chemotherapy treatment (yet).
Show all 15Show fewer
  • The first session takes place between two and six weeks after breast cancer surgery.
  • The second session takes before any follow-up treatment for breast cancer (radiotherapy or chemotherapy).
  • Chemotherapy group:
  • The patient is an adult oncological person between 18 and 75 years old who has been treated for cancer.
  • The participant has undergone breast cancer surgery but has not received any radiotherapy (yet).
  • Participant has a history of treatment with platinum- or taxane-based chemotherapeutic agents, and this treatment has been terminated no later than 6 weeks before the first session.
  • Healthy control group:
  • No history of cancer or chemotherapy treatment
  • Sex and age-matched to patient sample

Who cannot join

  • General (applies to all participants):
  • Participant has a history of mental or physical disorders or neurological disease beyond those related to cancer treatments.
  • Participant uses any prescription or non-prescription drugs on a regular basis which, in the investigator's opinion, might confound the results of the study.
  • Participant is currently participating or has been involved in testing an investigational drug in another clinical study within the last 4 weeks which, in the investigator's opinion, might confound the results of the study.
  • Participant suffered from peripheral neuropathy prior to the chemotherapeutic treatment (Only for patients).
  • Participant has (a history of) a lesion in the central nervous system that is known to possibly cause neuropathic pain: e.g. spinal cord injury, infarction localized in the brainstem or thalamus, syringomyelia, multiple sclerosis, or any other disorder of the CNS that, in the investigator's opinion, may cause neuropathic pain.
  • If applicable: Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Danny Koumans, MSc contact

+31648651471

danny.koumans@kuleuven.be

Jean-Jacques Orban de Xivry, PhD contact

jj.orban@kuleuven.be

Belgium1 site
  • KU Leuven, Sport Campus Arenberg, Gebouw De Nayer

    Leuven, Vlaams-Brabant, 3000

    Danny Koumans, MSc, +31648651471, danny.koumans@kuleuven.be

    Jean-Jacques Orban de Xivry, PhD, jj.orban@kuleuven.be

Other trials in Belgium

About this study

Official title: Multifaced Approach of Assessing Upper Extremity Proprioception in Breast Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most prevalent side-effects of chemotherapy, causing sensory and motor symptoms in patients. CIPN development is especially prevalent in chemotherapy treatment involving platinum- and taxane-based agents. The accompanying pain and deficits greatly impact the quality of life of these patients. Currently, patients are assessed for altered somatosensory using quantitative sensory testing (QST). The German Research Network on Neuropathic Pain (DFNS) has developed a standardized protocol which has been internationally recognized as approach for performing the QST. However, for proprioception the QST is limited to vibration assessments, making it limited as the only test to measure proprioception. Therefore, a comprehensive assessment of the proprioceptive functions is needed to better understand the influence CIPN has on the proprioception of patients, and thereby their quality of life.

In this project the effects of chemotherapy on somatosensory and proprioceptive functioning of breast cancer patients will be assessed in a cross-sectional study. This will be tested by comparing two groups of breast cancer patients and a healthy control group. Both patient groups will have undergone surgery for breast cancer, however, only one group will be tested after undergoing additional chemotherapy treatment. Thereby, the effects of chemotherapy between the surgery-only patient group and the chemotherapy patient group can tested. Furthermore, the investigators will compare both patient groups to sex- and age-matched healthy controls.

Being tested
Questionnaire - Edinburgh Handedness Assessment, Questionnaire - QuickDash, Questionnaire - EORTC QLQ-CIPN20, Questionnaire - Brief Pain Inventory (BPI), Questionnaire - Multidimensional Fatigue Inventory (MFI-20)
Keywords
Proprioception, Position Sense, CIPN, Breast Cancer, Chemotherapy-Induced Peripheral Neuropathy, Motor Control, Motion Capture, Marker-less, QST, Quantitative Sensory Testing, Robotic Assessment
Medical subject headings
Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Questionnaire - Edinburgh Handedness AssessmentOther

    The Edinburgh Handedness Assessment is a standardized questionnaire used to determine an individual's dominant hand preference across various everyday tasks.

  • Questionnaire - QuickDashOther

    The QuickDASH questionnaire is a validated, shortened version of the Disabilities of the Arm, Shoulder, and Hand (DASH) tool, and it is used in breast cancer patients to assess upper extremity function and disability

  • Questionnaire - EORTC QLQ-CIPN20Other

    The EORTC QLQ-CIPN20 is a validated questionnaire developed by the European Organisation for Research and Treatment of Cancer to assess chemotherapy-induced peripheral neuropathy (CIPN) and its impact on quality of life in cancer patients. It includes 20 items that evaluate sensory, motor, and autonomic symptoms-such as tingling, numbness, pain, and functional impairments in the hands and feet-experienced over the past week

  • Questionnaire - Brief Pain Inventory (BPI)Other

    The Brief Pain Inventory - Short Form (BPI-sf) is a 9-item, self-administered questionnaire designed to quickly assess:

    1. Pain Severity: Patients rate their pain at its worst, least, average, and current level over the past 24 hours using a 0-10 numeric scale.
    2. Pain Interference: Patients rate how much pain has interfered with seven aspects of daily life-general activity, mood, walking ability, normal work, relationships, sleep, and enjoyment of life-also on a 0-10 scale.
    3. Pain Relief: It includes questions about pain treatments, medications, and the percentage of relief experienced.
  • Questionnaire - Multidimensional Fatigue Inventory (MFI-20)Other

    The Multidimensional Fatigue Inventory (MFI-20) is a 20-item self-report questionnaire designed to assess five dimensions of fatigue in cancer patients and other populations:

    1. General Fatigue
    2. Physical Fatigue
    3. Reduced Activity
    4. Reduced Motivation
    5. Mental Fatigue
  • Assessment of cognitive function - Montreal Cognitive Assessment (MoCA)Other

    This is a brief cognitive assessment tool designed to detect possible mild cognitive impairments. Participants are asked questions which evaluate several cognitive domains, including: Attention and concentration, executive functions, memory, language, visuospatial skills, abstract thinking, calculation and orientation. Participants can receive up to 30 points for correctly answered questions, with a score of 26 or above considered normal.

  • Assessment of cognitive function - Spatial working memory taskOther

    In this task, for each trial, 16 squares are displayed on a circle in front of the participant. Then, between 3 to 6 of them become filled for a second before these stimuli disappear. One second later, a question mark appears in one of the 16 squares and the participant has to indicate whether this square was filled by a stimulus or not. Primary outcome of the task is working memory capacity.

  • Robotic assessment of motor control - Visually guided reaching taskDiagnostic test

    The participant will grab the handles of the robot which controls the cursor on the screen. To start a trial the participant moves the cursor to the starting position in the middle of the screen. One of four targets will appear which the participant is instructed to reach towards as quickly and as accurately as possible and stop within the target. After each reaching movement, the starting position becomes visible again and trials are repeated until each target has been repeated 5 times, so 20 trials in total. A composite score is computed by an algorithm devised by the Kinarm company and is used as outcome for this task.

  • Robotic assessment of proprioception - Bilateral whole arm position matching taskDiagnostic test

    During this task the robot moves the dominant hand to four different positions and the participant is asked to mirror the movement with the non-dominant hand. Larger differences in the position of the dominant and non-dominant hand are an indication of less accurate position sense. The primary outcome is the two-dimensional variability of the error between the target position and the matched position (error variability).

  • Robotic assessment of proprioception - Whole arm perceptual boundary taskDiagnostic test

    In this task, participants will be making arm reaching movements while their movement will be constrained by the robot to a certain angular deviation relative to a straight line to the target. Participants are then instructed to verbally indicate whether they were deviated to the left or to the right of a reference position (straight ahead). By gradually decreasing the angular deviation, it is possible to estimate how accurately participants could discriminate angular deviations. In order to obtain an efficient estimation of the perceptual boundary for each individual, a parameter estimation by sequential testing (PEST) procedure is applied. This algorithm starts with a large deviation and depending on the individual's response, it decreases the size of the deviation progressively until the deviation falls below a minimum threshold. The primary outcome is the slope of the psychometric curve obtained from the answers of the participants.

  • Robotic assessment of proprioception - Perturbation taskDiagnostic test

    This task assesses proprioceptive function by measuring force responses to mechanical perturbations during goal-directed reaching. Participants perform rapid reaching movements toward a visual target without visual feedback of the hand. On a subset of trials, the robotic device applies lateral perturbations of varying magnitudes that deviate the hand from the target. Participants are instructed to correct the movement and reach the target. The force exerted against the perturbation is recorded as an indicator of proprioceptive detection. To account for passive arm dynamics, participants also perform trials with a large target, which minimizes active corrective responses. Comparing force responses between small- and large-target conditions allows isolation of active responses to perturbations, providing a measure of proprioceptive sensitivity.

  • Robotic assessment of proprioception - Integration of vision and proprioceptionDiagnostic test

    This task looks at the unconscious integration of proprioception with vision. In this task, participants have to reach to target and stop on it. The hand of the participant is hidden from view but represented by a cursor that moves like the hand. On some trials, the cursor is deviated from its trajectory by a given angle (between -30 and 30°). On those trials, there is a discrepancy between the position of the hand and the position of the cursor. Once the participants have stopped on the target, they are requested to move back to the starting position in the absence of any visual information about their actual hand position. The direction in which the participants start to move is a readout of the integration of vision and proprioception of the hand position signals.

  • Robotic assessment of proprioception - Force matchingDiagnostic test

    Two versions of this task will be performed, distally (finger) and proximally (shoulder). Each version includes two different phases, a perception and a reproduction phase. In the perception phase, participants will be asked to memorize the force applied by the robot on the non-dominant arm. In the reproduction phase, participants will be required to move a slider that controls the amount of force exerted by the robot on the hand, with their dominant hand. The participant will try and reproduce the previously perceived force by manipulating the slider.

    The distal version will be performed using a small lever actuated by a motor. Participant will place their left index finger under the lever. Participants will again be asked to perceive and remember the force in the perception phase, and reproduce it using a slider in the reproduction phase.

  • Video-based assessment of proprioception - Wrist and shoulder bilateral position reproduction taskDiagnostic test

    For this task several variations to assess wrist and shoulder proprioception will performed. The experimenter will rotate the limb of the participant around a joint from a neutral position to a target position determined by a given angle (15, 30 or 45°). The participant will be asked to reproduce this position with the contralateral limb. All movements happen in the absence of any visual feedback about the limb position. Each target position is repeated ten times. For the shoulder task, the arms will be moved in the scapular plane (shoulder abduction). For the wrist, it will be in the sagittal plane (wrist flexion).

  • Video-based assessment of proprioception - Finger-to-finger reaching taskDiagnostic test

    At the start of each trial, the experimenter will place the active limb on the home position (~20cm away from the body midline and ~20cm in front of the torso). The experimenter will place the finger with the pulp of the finger placed upward at one of three possible positions (the target). The three possible target locations are ~20cm from the body midline, contralateral to the home position. They will be ~15, 20 and 25cm in front of the torso. The participants will be instructed to make a swift movement with the index finger of the active limb to the target finger, wait there for approximately 1s and then go back straight to the home position. Participants will perform 10 trials per target location, which will be pseudo-randomized (each target location will be used once per cycle of three trials).

  • Assessment of fatigue - Visual analogue scaleBehavioural

    Cognitive attention is an important factor for correct performance for many of the above mentioned tasks. Early-onset fatigue is a frequent problem for patients who have just undergone breast cancer treatment, thereby possibly affecting the results of our study. Therefore, participants will be asked to indicate their fatigue levels after every robotic task using a visual analogue scale (VAS) on a tablet, with the score ranging from 0-100 with zero no fatigue and 100 complete exhaustion.

  • Assessment of fear of movement - Visual analogue scaleBehavioural

    Fear for movement in patients who have just undergone surgery could impact the motor control and thereby affect the results of several proprioceptive tasks. Thus, participants will also be asked to indicate their level of fear to perform tasks after completion of each task, with the score ranging from 0-100 with zero being not reluctant and 100 extremely reluctant.

  • QST assessment of sensory function - Mechanical detection thresholdDiagnostic test

    In this task the detection threshold is tested using standardized monofilaments (Optihair2-Set, Marstock Nervtest, Germany) which exert forces between a range from 0.25 to 512 mN, depending on the thickness of the filament. The test starts by the researcher providing stimulation with the thickest monofilament which exerts the highest force. If the participant is able to detect the force, the researcher goes down in monofilament size until the participant is unable to detect a monofilament. The smallest size detected by the participant is established as the infra threshold. The process is then repeated in the opposite direction, with increasing size instead of decreasing. This is done until the participant is able to detect the stimulation again, which is then noted as the supra limit. This is repeated until five infra and supra limits each have been noted.

  • QST assessment of sensory function - Mechanical pain thresholdDiagnostic test

    During this task the pain threshold is assessed using a set of standardized pinpricks (MRC's PinPrick stimulators) which exert a force within a range between 8-512 mN. These pinpricks are weighted, which are progressively increasing, thereby increasing the exerted force. The participants are asked to describe the stimulation either as a blunt or as a sharp stimulation. The test is started using the pen with the lowest force exertion, and if the participant describes the stimulation as blunt the next increased progressive pen will be used. This will continue until the participant describes the subsequent stimulation as sharp. When this happens, that pen is noted as the supra threshold. The process is then repeated in the opposite direction, now with deceasing force stimuli, until the participants describe the stimulation as blunt, which will then be noted as the infra threshold. This is repeated until both infra and supra have been noted 5 times each.

  • QST assessment of sensory function - Vibration detection thresholdDiagnostic test

    The vibration detection threshold is used in the QST as a proprioceptive measurement. It is performed with a Rydel-Seiffer tuning fork which vibrates at a frequency of 128 Hz. During the assessment, the tuning fork is placed on several boney structures, including the thumb, wrist, elbow, and the shoulder. The tuning fork is struck causing it to vibrate and is then subsequently placed on the boney structure. The tuning fork has a damping scale, which is a triangle with a numbered scale along the height of the triangle. The visibility of the tip of the triangle while the fork is vibrating will depend on the amplitude of the vibration. While the tuning fork is placed on a boney structure, the participant has to indicate when they cannot detect the vibration anymore. At this moment, the researcher will read the number from the scale at which the tip of the triangle is currently visible. This represents the amplitude of the vibration the participant is able to detect.

  • Assessment of sensory function - BumpsDiagnostic test

    In this task, participants are presented with five plates (2x2cm). There is a small bump in one of them. The participant is asked to indicate on which plate a bump is present and how confident they are about their choice on a scale from 1 to 3 (not certain at all, more or less certain, without any doubt). There are five different bump heights: 5, 10, 15, 20 and 25 μm. Each bump height is presented three times. This is done without vision as the plates are hidden from the participants. The primary outcome is the bump detection threshold, defined as the lowest bump height that was successfully detected in two of the three trials and the next higher bumps were successfully detected on 3/3 trials.

  • Assessment of range of motionOther

    The range of motion for the arms will be tested using a digital goniometer (EasyAngle, Meloq, Stockholm, Sweden)). The degree of maximal active movement will be recorded of: 1) humerothoracic elevation in the scapular plane; 2) arm external rotation in 0° humerothoracic abduction position and 3) arm external rotation in 90° humerothoracic abduction position. The digital goniometer will be placed on the upper arm and active range of motion (°) are assessed at both sides for the three movement tasks. For arm elevation, the participant will start with the arms straight alongside the body and the thumbs pointing forward and without shoulder girdle elevation. For the external rotation task at 0° and 90° of abduction, the elbow will be flexed to 90°. For the external rotation task at 90° of abduction, an abduction pillow will be added to support the upper arm.

  • Assessment of total relative arm volume - Arm volumeOther

    For the arm, a perimeter, which is a flexible stainless-steel bar with a tapeline fixed every 4 cm and a weight of 20 g at the end of each tapeline, will be used to measure the circumference, allowing us to calculate the volume. The perimeter will be placed on each arm of the participant subsequently allowing the circumference of each arm to be determined in 4 cm intervals. Afterwards, the volume of the arm is calculated using a truncated cone, the relative arm volume (%) will be calculated by the formula: ((volume of the affected arm - volume of the non-affected arm) / volume of the non-affected arm) x 100. Correction for arm dominance was done by adjusting the arm volume of the non-dominant arm with 3.3% because literature indicates that the non-dominant arm is on average 3.3.% smaller than the dominant arm.

  • Assessment of total relative arm volume - Hand volumeOther

    For the hand, bilateral water displacement method using a volumeter will be used. The volumeter is filled with water, allowed to settle at room temperature, and the patient is asked to lower their hand slowly, with the forearm pronated and the fingers resting in adduction, into the volumeter until the web of the middle and ring finger rest on the stop dowl. The patient remains still until there is more than 5 s between each drip at the overflow. The displaced water will be collected in a beaker. The amount of water displacement is weighed in kilograms, and converted to milliliters (1kg =1000mL). Afterwards the total volume (mL) of the arm and hand can be calculated by taking the sum of the two measurements.

Study groups in NCT07367711
Study groupRoleWhat they receive
Surgery onlyBreast cancer patients who have only undergone surgery for breast cancer and no other cancer treatment yet. Patients will be measured between 2 to 6 weeks post-surgery.
Receives: Other: Questionnaire - Edinburgh Handedness Assessment; Other: Questionnaire - QuickDash; Other: Questionnaire - EORTC QLQ-CIPN20; Other: Questionnaire - Brief Pain Inventory (BPI); Other: Questionnaire - Multidimensional Fatigue Inventory (MFI-20); Other: Assessment of cognitive function - Montreal Cognitive Assessment (MoCA); Other: Assessment of cognitive function - Spatial working memory task; Diagnostic Test: Robotic assessment of motor control - Visually guided reaching task; Diagnostic Test: Robotic assessment of proprioception - Bilateral whole arm position matching task; Diagnostic Test: Robotic assessment of proprioception - Whole arm perceptual boundary task; Diagnostic Test: Robotic assessment of proprioception - Perturbation task; Diagnostic Test: Robotic assessment of proprioception - Integration of vision and proprioception; Diagnostic Test: Robotic assessment of proprioception - Force matching; Diagnostic Test: Video-based assessment of proprioception - Wrist and shoulder bilateral position reproduction task; Diagnostic Test: Video-based assessment of proprioception - Finger-to-finger reaching task; Behavioral: Assessment of fatigue - Visual analogue scale; Behavioral: Assessment of fear of movement - Visual analogue scale; Diagnostic Test: QST assessment of sensory function - Mechanical detection threshold; Diagnostic Test: QST assessment of sensory function - Mechanical pain threshold; Diagnostic Test: QST assessment of sensory function - Vibration detection threshold; Diagnostic Test: Assessment of sensory function - Bumps; Other: Assessment of range of motion; Other: Assessment of total relative arm volume - Arm volume; Other: Assessment of total relative arm volume - Hand volume
Surgery + ChemotherapyBreast cancer patients who have undergone surgery for breast cancer and chemotherapy (with taxane- or platinum-based agents) and no other cancer treatment yet. Patients will be measured no later than 6 weeks after their last chemotherapy session.
Receives: Other: Questionnaire - Edinburgh Handedness Assessment; Other: Questionnaire - QuickDash; Other: Questionnaire - EORTC QLQ-CIPN20; Other: Questionnaire - Brief Pain Inventory (BPI); Other: Questionnaire - Multidimensional Fatigue Inventory (MFI-20); Other: Assessment of cognitive function - Montreal Cognitive Assessment (MoCA); Other: Assessment of cognitive function - Spatial working memory task; Diagnostic Test: Robotic assessment of motor control - Visually guided reaching task; Diagnostic Test: Robotic assessment of proprioception - Bilateral whole arm position matching task; Diagnostic Test: Robotic assessment of proprioception - Whole arm perceptual boundary task; Diagnostic Test: Robotic assessment of proprioception - Perturbation task; Diagnostic Test: Robotic assessment of proprioception - Integration of vision and proprioception; Diagnostic Test: Robotic assessment of proprioception - Force matching; Diagnostic Test: Video-based assessment of proprioception - Wrist and shoulder bilateral position reproduction task; Diagnostic Test: Video-based assessment of proprioception - Finger-to-finger reaching task; Behavioral: Assessment of fatigue - Visual analogue scale; Behavioral: Assessment of fear of movement - Visual analogue scale; Diagnostic Test: QST assessment of sensory function - Mechanical detection threshold; Diagnostic Test: QST assessment of sensory function - Mechanical pain threshold; Diagnostic Test: QST assessment of sensory function - Vibration detection threshold; Diagnostic Test: Assessment of sensory function - Bumps; Other: Assessment of range of motion; Other: Assessment of total relative arm volume - Arm volume; Other: Assessment of total relative arm volume - Hand volume
Healthy controlHealthy sex- and age-matched controls. Participants should have no history of any neurological disorder or cancer.
Receives: Other: Questionnaire - Edinburgh Handedness Assessment; Other: Questionnaire - QuickDash; Other: Questionnaire - EORTC QLQ-CIPN20; Other: Questionnaire - Brief Pain Inventory (BPI); Other: Questionnaire - Multidimensional Fatigue Inventory (MFI-20); Other: Assessment of cognitive function - Montreal Cognitive Assessment (MoCA); Other: Assessment of cognitive function - Spatial working memory task; Diagnostic Test: Robotic assessment of motor control - Visually guided reaching task; Diagnostic Test: Robotic assessment of proprioception - Bilateral whole arm position matching task; Diagnostic Test: Robotic assessment of proprioception - Whole arm perceptual boundary task; Diagnostic Test: Robotic assessment of proprioception - Perturbation task; Diagnostic Test: Robotic assessment of proprioception - Integration of vision and proprioception; Diagnostic Test: Robotic assessment of proprioception - Force matching; Diagnostic Test: Video-based assessment of proprioception - Wrist and shoulder bilateral position reproduction task; Diagnostic Test: Video-based assessment of proprioception - Finger-to-finger reaching task; Behavioral: Assessment of fatigue - Visual analogue scale; Behavioral: Assessment of fear of movement - Visual analogue scale; Diagnostic Test: QST assessment of sensory function - Mechanical detection threshold; Diagnostic Test: QST assessment of sensory function - Mechanical pain threshold; Diagnostic Test: QST assessment of sensory function - Vibration detection threshold; Diagnostic Test: Assessment of sensory function - Bumps; Other: Assessment of range of motion; Other: Assessment of total relative arm volume - Arm volume; Other: Assessment of total relative arm volume - Hand volume

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proprioceptive variability

    Within-subject variability/precision of proprioceptive estimates during repeated matching or reaching trials, indicating consistency of position sense. Measures will be derived from robotic tasks (including arm position matching, and perceptual boundary (slope) tasks) and video-based DeepLabCut tasks (including the joint position matching and finger-to-finger reaching tasks). Example metrics: standard deviation of repeated matches or within-subject SD of errors.

    Measured: Baseline (across two assessment visits within 10 days of each other)

Secondary outcomes (9)
  1. Proprioceptive bias

    Systematic directional error (bias) in reproduced limb positions or reaches, reflecting systematic over- or under-shoot. Measures will be derived from KINARM robotic tasks (including arm position matching, and perceptual boundary tasks) and video-based tasks (including the joint position matching and finger-to-finger reaching tasks). Example metrics: signed error aggregated across trials.

    Measured: Baseline (across two assessment visits within 10 days of each other)

  2. Proprioceptive accuracy

    Overall proprioceptive accuracy across upper-limb tasks, represented by spatial error in position/target matching and reach tasks. Measures are derived from robotic tasks (including arm position matching, and perceptual boundary tasks) and video-based tasks (including the joint position matching and finger-to-finger reaching tasks). Example metrics: mean absolute error

    Measured: Baseline (across two assessment visits within 10 days of each other)

  3. Force perception accuracy and variability

    Accuracy and consistency of perceived vs produced force during force-matching tasks (finger and whole-arm robotic force matching). Includes measures of mean error and variability in force reproduction.

    Measured: Baseline (during first assessment visit)

  4. Multisensory integration performance

    Performance on tasks assessing the integration of proprioceptive and visual information, quantified during the integration of vision and proprioception task by looking at the influence of the visual perturbation on the direction of the return movement (same outcome as in Van De Plas and Orban de Xivry 2025, https://www.biorxiv.org/content/10.1101/2025.05.22.655043v2.full).

    Measured: Baseline (during first assessment visit)

  5. Reaction to Proprioceptive perturbation

    Response to externally applied mechanical perturbations quantified during a robotic reaching task by isolating active force responses from passive arm dynamics. The outcome is derived from force exerted against perturbations during small-target trials relative to wide-target trials, summarized as the slope of a psychometric function reflecting the probability of detecting and counteracting perturbations across perturbation magnitudes.

    Measured: Baseline (during first assessment visit)

  6. Somatosensory detection thresholds

    Through the mechanical detection threshold task, the geometrical mean for the 5 infra thresholds measured and the 5 supra thresholds are determined, representing the somatosensory detection threshold.

    Measured: Baseline (during second assessment visit)

  7. Somatosensory pain thresholds

    Through the mechanical pain threshold task the geometrical mean for the 5 infra thresholds measured and the 5 supra thresholds are determined, representing the somatosensory pain threshold.

    Measured: Baseline (during second assessment visit)

  8. Somatosensory Vibration detection thresholds

    Detection threshold is expressed through the Rydel-Seiffer score (0-8), which represents the smallest amplitude of vibration (frequency of 64 Hz) the participant is able to detect. A higher Rydel-Seiffer score equals a lower vibration amplitude.

    Measured: Baseline (during second assessment visit)

  9. Tactile threshold

    Through the bumps task, the geometrical mean for the 3 infra thresholds measured and the 3 supra thresholds are determined, representing the tactile threshold.

    Measured: Baseline (during second assessment visit)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jan 2026
  2. Study startFeb 2026 (estimated)
  3. Primary completionNov 2027 (estimated)
  4. Study completionNov 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
145 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07367711
Sponsor's protocol ID
S70774
Acronym
ProprioCIPN
Status last verified
Jan 2026
First submitted
5 Jan 2026
Last updated
26 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Van De Plas S, Orban de Xivry JJ. Age-related changes in proprioception are of limited size, outcome-dependent and task-dependent. Geroscience. 2026 Feb 4. doi: 10.1007/s11357-025-02053-2. Online ahead of print.

    PubMed 41639366
  • Rinderknecht MD, Popp WL, Lambercy O, Gassert R. Reliable and Rapid Robotic Assessment of Wrist Proprioception Using a Gauge Position Matching Paradigm. Front Hum Neurosci. 2016 Jun 29;10:316. doi: 10.3389/fnhum.2016.00316. eCollection 2016.

    PubMed 27445756
  • Parthasharathy M, Mantini D, Orban de Xivry JJ. Increased upper-limb sensory attenuation with age. J Neurophysiol. 2022 Feb 1;127(2):474-492. doi: 10.1152/jn.00558.2020. Epub 2021 Dec 22.

    PubMed 34936521
  • Rand MK, Heuer H. A condition that produces sensory recalibration and abolishes multisensory integration. Cognition. 2020 Sep;202:104326. doi: 10.1016/j.cognition.2020.104326. Epub 2020 May 25.

    PubMed 32464344
  • Vandevoorde K, Orban de Xivry JJ. Does proprioceptive acuity influence the extent of implicit sensorimotor adaptation in young and older adults? J Neurophysiol. 2021 Oct 1;126(4):1326-1344. doi: 10.1152/jn.00636.2020. Epub 2021 Aug 4.

    PubMed 34346739
  • Herter TM, Scott SH, Dukelow SP. Systematic changes in position sense accompany normal aging across adulthood. J Neuroeng Rehabil. 2014 Mar 25;11:43. doi: 10.1186/1743-0003-11-43.

    PubMed 24666888
  • Dukelow SP, Herter TM, Moore KD, Demers MJ, Glasgow JI, Bagg SD, Norman KE, Scott SH. Quantitative assessment of limb position sense following stroke. Neurorehabil Neural Repair. 2010 Feb;24(2):178-87. doi: 10.1177/1545968309345267. Epub 2009 Sep 30.

    PubMed 19794134
  • Coderre AM, Zeid AA, Dukelow SP, Demmer MJ, Moore KD, Demers MJ, Bretzke H, Herter TM, Glasgow JI, Norman KE, Bagg SD, Scott SH. Assessment of upper-limb sensorimotor function of subacute stroke patients using visually guided reaching. Neurorehabil Neural Repair. 2010 Jul-Aug;24(6):528-41. doi: 10.1177/1545968309356091. Epub 2010 Mar 16.

    PubMed 20233965
  • Kennedy WR, Selim MM, Brink TS, Hodges JS, Wendelschafer-Crabb G, Foster SX, Nolano M, Provitera V, Simone DA. A new device to quantify tactile sensation in neuropathy. Neurology. 2011 May 10;76(19):1642-9. doi: 10.1212/WNL.0b013e318219fadd.

    PubMed 21555731
  • Vandevoorde K, Orban de Xivry JJ. Why is the explicit component of motor adaptation limited in elderly adults? J Neurophysiol. 2020 Jul 1;124(1):152-167. doi: 10.1152/jn.00659.2019. Epub 2020 May 27.

    PubMed 32459553
  • Christou AI, Miall RC, McNab F, Galea JM. Individual differences in explicit and implicit visuomotor learning and working memory capacity. Sci Rep. 2016 Nov 8;6:36633. doi: 10.1038/srep36633.

    PubMed 27824129
  • Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x.

    PubMed 15817019
  • Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995 Apr;39(3):315-25. doi: 10.1016/0022-3999(94)00125-o.

    PubMed 7636775
  • Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004 Sep-Oct;20(5):309-18. doi: 10.1097/00002508-200409000-00005.

    PubMed 15322437
  • Lavoie Smith EM, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res. 2013 Dec;22(10):2787-99. doi: 10.1007/s11136-013-0379-8. Epub 2013 Mar 30.

    PubMed 23543373

Questions about this trial

What is this clinical trial studying?

An observational study of CIPN - Chemotherapy-Induced Peripheral Neuropathy and Chemotherapy-Induced Peripheral Neuropathy, run by KU Leuven at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Danny Koumans, MSc (+31648651471, danny.koumans@kuleuven.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proprioceptive variability (time frame: Baseline (across two assessment visits within 10 days of each other)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07367711, which also lists 16 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in